Patents by Inventor Frank Hilberg

Frank Hilberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180346559
    Abstract: The invention relates to the combined use of certain bispecific, VEGF and Ang2 binding molecules with PD1 antagonists for the treatment of cancer. It further relates to pharmaceutical compositions and kits comprising such binding molecules and antagonists.
    Type: Application
    Filed: June 1, 2018
    Publication date: December 6, 2018
    Inventors: Frank Hilberg, Marco Hans Hofmann, Markus Reschke, Flavio Solca
  • Publication number: 20180243308
    Abstract: The present invention relates to a pharmaceutical combination which may be useful for the treatment of diseases which involve cell proliferation, which involve migration or apoptosis of myeloma cells, which involve angiogenesis or which involve fibrosis. The invention also relates to a method for the treatment of said diseases, comprising simultaneous, separate or sequential administration of effective amounts of specific active compounds and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compounds and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.
    Type: Application
    Filed: May 1, 2018
    Publication date: August 30, 2018
    Inventors: Martin Friedrich STEFANIC, Frank HILBERG, Rolf KAISER, David SHAPIRO
  • Publication number: 20160250218
    Abstract: The present invention relates to a pharmaceutical combination which may be useful for the treatment of diseases which involve cell proliferation, which involve migration or apoptosis of myeloma cells, which involve angiogenesis or which involve fibrosis. The invention also relates to a method for the treatment of said diseases, comprising simultaneous, separate or sequential administration of effective amounts of specific active compounds and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compounds and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.
    Type: Application
    Filed: May 6, 2016
    Publication date: September 1, 2016
    Inventors: Martin Friedrich STEFANIC, Frank HILBERG, Rolf KAISER, David SHAPIRO
  • Publication number: 20150265610
    Abstract: The present invention relates to a pharmaceutical combination for the treatment of diseases which involves cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis. The invention also relates to a method for the treatment of said diseases, comprising co-administration of effective amounts of specific active compounds and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compounds and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.
    Type: Application
    Filed: June 5, 2015
    Publication date: September 24, 2015
    Inventors: Martin Friedrich STEFANIC, Frank HILBERG, Gerd MUNZERT, Flavio SOLCA, Anke BAUM, Jacobus C.A. van MEEL
  • Publication number: 20150174126
    Abstract: The present invention relates to a pharmaceutical combination which may be useful for the treatment of diseases which involve cell proliferation, which involve migration or apoptosis of myeloma cells, which involve angiogenesis or which involve fibrosis. The invention also relates to a method for the treatment of said diseases, comprising simultaneous, separate or sequential administration of effective amounts of specific active compounds and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compounds and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.
    Type: Application
    Filed: March 5, 2015
    Publication date: June 25, 2015
    Inventors: Martin Friedrich STEFANIC, Frank HILBERG, Rolf KAISER, David SHAPIRO
  • Publication number: 20140187563
    Abstract: The invention relates to new methods for the treatment of oncological and fibrotic disease comprising the combined administration of an inhibitor of vascular endothelial growth factor receptors (VEGFRs) in conjunction with a thrombin inhibitor.
    Type: Application
    Filed: March 6, 2014
    Publication date: July 3, 2014
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Joanne VAN RYN, Frank HILBERG, Pilar GARIN-CHESA
  • Publication number: 20140057898
    Abstract: The present invention relates to a pharmaceutical combination for the treatment of diseases which involves cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis. The invention also relates to a method for the treatment of said diseases, comprising co-administration of effective amounts of specific active compounds and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compounds and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.
    Type: Application
    Filed: November 4, 2013
    Publication date: February 27, 2014
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Martin Friedrich STEFANIC, Frank HILBERG, Gerd MUNZERT, Flavio SOLCA, Anke BAUM, Jacobus C.A. van MEEL
  • Publication number: 20130237549
    Abstract: The present invention relates to a pharmaceutical combination which may be useful for the treatment of diseases which involve cell proliferation, which involve migration or apoptosis of myeloma cells, which involve angiogenesis or which involve fibrosis. The invention also relates to a method for the treatment of said diseases, comprising simultaneous, separate or sequential administration of effective amounts of specific active compounds and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compounds and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.
    Type: Application
    Filed: April 24, 2013
    Publication date: September 12, 2013
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Martin Friedrich STEFANIC, Frank HILBERG, Rolf KAISER, David SHAPIRO
  • Patent number: 8207349
    Abstract: The present invention encompasses compounds of the general formula (1) in which R1 to R3 are defined as in claim 1, which are suitable for treating diseases which are characterized by excessive or anomalous cell proliferation, and their use for producing a pharmaceutical having the abovementioned properties.
    Type: Grant
    Filed: January 11, 2010
    Date of Patent: June 26, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Bodo Betzemeier, Trixi Brandl, Steffen Breitfelder, Ralph Brueckner, Thomas Gerstberger, Michael Gmachl, Matthias Grauert, Frank Hilberg, Christoph Hoenke, Matthias Hoffmann, Maria Impagnatiello, Dirk Kessler, Christian Klein, Bernd Krist, Udo Maier, Darryl McConnell, Charlotte Reither, Stefan Scheuerer, Andreas Schoop, Norbert Schweifer, Oliver Simon, Martin Steegmaier, Steffen Steurer, Irene Waizenegger, Ulrike Weyer-Czernilofsky, Andreas Zoephel
  • Publication number: 20120157472
    Abstract: The present invention relates to a method of treating patients suffering from colorectal cancer characterized by coadministration of BIBF 1120 and BIBW 2992, wherein in said method BIBF 1120 is administered according to a continuous daily regimen and BIBW 2992 is administered according to a weekly alternating on-off regimen, pharmaceutical compositions and kits suitable for this method as well as their preparation.
    Type: Application
    Filed: January 13, 2010
    Publication date: June 21, 2012
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Annette Larsen, Anke Baum, Frank Hilberg, Flavio Solca
  • Publication number: 20120142703
    Abstract: The invention relates to new methods for the treatment of oncological and fibrotic disease comprising the combined administration of an inhibitor of vascular endothelial growth factor receptors (VEGFRs) in conjunction with a thrombin inhibitor.
    Type: Application
    Filed: May 11, 2010
    Publication date: June 7, 2012
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Joanne Van Ryn, Frank Hilberg, Pilar Garin-Chesa
  • Patent number: 8048036
    Abstract: A hypodermic needle assembly configured such that the movement of a needle shield into position to block the needle tip occurs as a direct consequence of a longitudinal force applied by insertion of a syringe plunger is provided. The hypodermic needle assembly according to the present invention comprises a needle, a needle hub, and a safety spring clip assembly, the safety spring clip assembly being configured to automatically launch from the needle hub and slide along the needle until the spring clip meets a needle stop at the needle tip, thus preventing the guard from being removed from the needle shaft. A method of using the hypodermic needle assembly according to the present invention is also provided, which includes the method of launching the spring clip with a syringe having multiple advancing mechanisms.
    Type: Grant
    Filed: July 31, 2006
    Date of Patent: November 1, 2011
    Assignee: B. Braun Melsungen AG
    Inventors: Kevin Woehr, Helmut Freigang, Juergen Fuchs, Juergen Reuter, Klaus Siemon, Joerg Wende, Frank Hilberg
  • Patent number: 7989474
    Abstract: The invention relates to a method of treating immunologic diseases or pathological conditions involving an immunologic component using certain Lck inhibitors already known as kinase inhibitors for therapy in oncology, optionally in combination with one or more other drugs selected from NSAIDs, steroids, DMARDs, immunsuppressives, biologic response modifiers and antinfectives, pharmaceutical compositions comprising said Lck inhibitors together with said other drugs, and the use of the Lck inhibitors for the manufacture of a pharmaceutical composition for the treatment of immunologic diseases or pathological conditions involving an immunologic component.
    Type: Grant
    Filed: December 12, 2008
    Date of Patent: August 2, 2011
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Gerald Juergen Roth, Armin Heckel, Rainer Walter, Frank Hilberg, Rudolf Hauptmann, Martin Fredrich Stefanic, Florian Colbatzky, Steffan Ernest
  • Publication number: 20110178099
    Abstract: The present invention relates to a pharmaceutical combination which may be useful for the treatment of diseases which involve cell proliferation, which involve migration or apoptosis of myeloma cells, which involve angiogenesis or which involve fibrosis. The invention also relates to a method for the treatment of said diseases, comprising simultaneous, separate or sequential administration of effective amounts of specific active compounds and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compounds and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.
    Type: Application
    Filed: June 4, 2009
    Publication date: July 21, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Martin Friedrich Stefanic, Frank Hilberg, Rolf Kaiser, David Shapiro
  • Publication number: 20110171289
    Abstract: The present invention relates to a pharmaceutical combination for the treatment of diseases which involves cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis. The invention also relates to a method for the treatment of said diseases, comprising co-administration of effective amounts of specific active compounds and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compounds and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.
    Type: Application
    Filed: November 9, 2010
    Publication date: July 14, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Martin Friedrich STEFANIC, Frank HILBERG, Gerd MUNZERT, Flavio SOLCA, Anke BAUM, Jacobus C.A. van MEEL
  • Publication number: 20110136826
    Abstract: The present invention relates to a pharmaceutical combination for the treatment of diseases which involves cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis. The invention also relates to a method for the treatment of said diseases, comprising co-administration of effective amounts of specific active compounds and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compounds and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.
    Type: Application
    Filed: November 15, 2010
    Publication date: June 9, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Frank HILBERG, Flavio SOLCA, Anke BAUM, Jacobus C.A. van MEEL
  • Patent number: 7922698
    Abstract: A hypodermic needle assembly configured such that the movement of a needle shield into position to block the needle tip occurs as a direct consequence of a longitudinal force applied by insertion of a syringe plunger is provided. The hypodermic needle assembly according to the present invention includes a needle, a needle hub, and a safety spring clip assembly, the safety spring clip assembly being configured to automatically launch from the needle hub and slide along the needle to shield the needle tip, thus preventing accidental contact with the needle tip. Additional mechanisms for launching the safety spring clip are also provided, which include using a trigger ring for rotating and launching the safety spring clip. Methods for making and using the hypodermic needle assemblies are also disclosed.
    Type: Grant
    Filed: April 4, 2008
    Date of Patent: April 12, 2011
    Assignee: B. Braun Melsungen AG
    Inventors: Hermann Riesenberger, Helmut Freigang, Juergen Fuchs, Juergen Reuter, Klaus Siemon, Frank Hilberg, Kevin Woehr
  • Publication number: 20110039863
    Abstract: The present invention relates to a pharmaceutical combination for the treatment of diseases which involves cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis. The invention also relates to a method for the treatment of said diseases, comprising co-administration of effective amounts of specific active compounds and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compounds and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.
    Type: Application
    Filed: October 26, 2010
    Publication date: February 17, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Frank HILBERG, Flavio SOLCA, Anke BAUM, Jacobus C.A. van MEEL
  • Patent number: 7858616
    Abstract: The present invention relates to indolinone derivatives, substituted in the 6-position, of the formula in which R1 to R6 and X are as defined in Claim 1, to their tautomers, enantiomers, diastereomers, to their mixtures and to their salts, in particular their physiologically acceptable salts, which have useful pharmacological properties, in particular in inhibiting action on various receptor tyrosine kinases and on the proliferation of endothelial cells and various tumour cells, to medicaments comprising these compounds, to their use and to processes for their preparation.
    Type: Grant
    Filed: April 10, 2009
    Date of Patent: December 28, 2010
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Gerald Juergen Roth, Armin Heckel, Thorsten Lehmann-Lintz, Joerg Kley, Frank Hilberg, Jacobus C. A. Van Meel, Ulrike Tontsch-Grunt
  • Patent number: 7846936
    Abstract: The present invention relates to a pharmaceutical combination for the treatment of diseases which involves cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis. The invention also relates to a method for the treatment of said diseases, comprising co-administration of effective amounts of specific active compounds and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compounds and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.
    Type: Grant
    Filed: June 17, 2008
    Date of Patent: December 7, 2010
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Frank Hilberg, Flavio Solca, Anke Baum, Jacobus C. A. van Meel